BiotechTube

Cannabidiol Oral Solution [Epidiolex]

ApprovedActive
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

Conditions

Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

Trial Timeline

Jun 29, 2023 → Mar 26, 2026

NCT ID
NCT05864846

About Cannabidiol Oral Solution [Epidiolex]

Cannabidiol Oral Solution [Epidiolex] is a approved stage product being developed by Jazz Pharmaceuticals for Tuberous Sclerosis Complex Associated Neuropsychiatric Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05864846. Target conditions include Tuberous Sclerosis Complex Associated Neuropsychiatric Disease.

What happened to similar drugs?

0 of 7 similar drugs in Tuberous Sclerosis Complex Associated Neuropsychiatric Disease were approved

Approved (0) Terminated (1) Active (6)
🔄Everolimus (RAD001) + Everolimus PlaceboNovartisPhase 3
🔄Everolimus + PlaceboNovartisPhase 3
🔄RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)NovartisPhase 3
🔄everolimusNovartisPhase 3
❌GWP42003-PJazz PharmaceuticalsPhase 3
🔄GWP42003-PJazz PharmaceuticalsPhase 3
🔄GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
20
Activity
12
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05864846ApprovedActive

Competing Products

13 competing products in Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

See all competitors
ProductCompanyStageHype Score
Everolimus (RAD001) + Everolimus PlaceboNovartisPhase 3
40
Everolimus + PlaceboNovartisPhase 3
40
RAD001NovartisPhase 1/2
32
Placebo + Everolimus (RAD001)NovartisPhase 2
31
RAD001 + PlaceboNovartisPhase 2
35
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)NovartisPhase 3
40
EverolimusNovartisPhase 1/2
32
everolimus (RAD001)NovartisPhase 1/2
32
everolimusNovartisPhase 3
44
sirolimusPfizerPhase 2
31
GWP42003-PJazz PharmaceuticalsPhase 3
29
GWP42003-PJazz PharmaceuticalsPhase 3
37
GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3
37